Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Chonju, Korea, Republic of Clinical Trials

A listing of Chonju, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (23) clinical trials

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer

Purpose The purpose of this Phase III study is to determine if regorafenib improves overall survival in patients with Advanced Gastro-Oesophageal Carcinoma. Who is it for: You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with advanced (metastatic or …

Phase

0.0 miles

Learn More »

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

The primary objectives of this study are: Part 1: To evaluate the objective response rate (ORR) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum based doublet chemotherapy in the first-line treatment of patients with advanced squamous or nonsquamous non-small cell lung cancer (NSCLC) in the subgroup of patients whose tumors express programmed …

Phase

0.0 miles

Learn More »

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive With or Without Mixed Features

To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features; 2) To evaluate the efficacy and safety …

Phase

0.0 miles

Learn More »

An Efficacy Study Comparing Ponatinib Versus Imatinib Administered in Combination With Reduced-Intensity Chemotherapy in Participants With Newly Diagnosed Ph+ ALL

The drug being tested in this study is called ponatinib. Ponatinib is being tested to treat people who have newly diagnosed Ph+ ALL. This study will look at the efficacy of ponatinib in participants in addition to standard care. The study will enroll approximately 230-320 participants. Participants will be randomized …

Phase

0.0 miles

Learn More »

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)

The main purpose of this study is to evaluate the efficacy of bemarituzumab (FPA144), which is a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with Gastric Cancer as measured by overall survival.

Phase

0.0 miles

Learn More »

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

This study evaluates the efficacy, safety, and tolerability of ustekinumab in participants with active SLE according to Systemic Lupus International Collaborating Clinics (SLICC) criteria Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score greater than (>=) 6, despite receiving one or more standard-of-care treatments (example, immunomodulators, antimalarial drugs, and/or glucocorticoids). …

Phase

0.0 miles

Learn More »

Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin

Multi center, randomized, double-blind, parallel-group, therapeutic confirmatory study Primary Outcome Measure: The mean percent change of Non-HDL Cholesterol [Time Frame: from baseline at week 8] Secondary Outcome Measures: The achievement rate of LDL-C<100mg/dl, Non-HDL-C<130mg/dl [Time Frame: from baseline at week 8] The mean percent change of LDL-C, HDL-C, TG, TC, …

Phase

0.0 miles

Learn More »

Evaluation of the Long Term Safety Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ) in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1 2 or 3.

The goal of this Phase III study is to evaluate the long-term safety, tolerability, and efficacy of OKZ in subjects with moderately to severely active RA who previously completed 24 weeks of double-blind treatment with OKZ in the core studies. OKZ is expected to reduce the disease activity and induce …

Phase

0.0 miles

Learn More »

A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer

Background of Hypothesis A. JCOG (Japanese Clinical Oncology Group) 9501 Study : Addition of aorta lymph node dissection to D2 lymph node dissection does not increase survival rate. Wide range of operation is not always the best treatment. If invasion rate can be kept as minimal as possible while maintaining …

Phase

0.0 miles

Learn More »